Raffit Hassan, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Raffit Hassan, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06885697 · Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI) · recruiting · Mesothelioma, Neoplasms, Stomach Neoplasms · principal investigator
- Ph1NCT04840615 · Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- N/ANCT03830229 · Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1National Cancer Institute (NCI) · recruiting · Mesothelioma, Families · principal investigator
- Ph2NCT03644550 · Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Ph2NCT03531840 · Olaparib in People With Malignant MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma · principal investigator
- Ph1NCT03436732 · Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Ph2NCT02839681 · Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaNational Cancer Institute (NCI) · terminated · Lung Neoplasms · principal investigator
- Ph1NCT02798536 · Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma · principal investigator
- N/ANCT01950572 · Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaNational Cancer Institute (NCI) · recruiting · Thymoma, Stomach Neoplasms, Pancreatic Neoplasms · principal investigator
- Ph1NCT01445392 · SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Early Ph1NCT01413451 · Amatuximab for High Mesothelin CancersNational Cancer Institute (NCI) · terminated · Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms · principal investigator
- Ph1/Ph2NCT01362790 · SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms · principal investigator
- Ph2NCT01160458 · Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With ChemotherapyNational Cancer Institute (NCI) · completed · Pleural Mesothelioma, Peritoneal Mesothelioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.